The nano-/microscale UiO-66-NH2 metal–organic framework (MOF) materials were successfully prepared with a uniform size of about 350–400 nm and structurally characterized. Soybean epoxide hydrolase (SEH), a useful hydrolase for synthesis of valuable vicinal diols, was for the first time efficiently immobilized onto the prepared UiO-66-NH2 MOF. The resulting novel nano-/microbiocatalyst SEH@UiO-66-NH2 manifested high SEH loading (87.3 mg/g) and enzyme activity recovery (88.0%). The novel SEH@UiO-66-NH2 greatly surpassed the free SEH with resepct to pH stability, thermostability, and tolerance to organic solvents. SEH@UiO-66-NH2 retained more than 17.6 U activity after 2 h of incubation at 45 °C, whereas free SEH maintained around 10.1 U activity under the same conditions. After storage at 4 °C for 4 weeks, the prepared SEH@UiO-66-NH2 still retained around 97.5% of its initial activity. The significant enhancements resulted from the increase of structural rigidity of SEH@UiO-66-NH2, which was demonstrated by the secondary structure analysis of the enzyme. The optimun pH and tempearture of SEH@UiO-66-NH2 were significantly superior to the corresponding levels of its free counterpart. Also, SEH@UiO-66-NH2 manifested markedly enhanced enzyme–substrate affinity and catalytic efficiency compared to free SEH, as supported by a lower apparent Km value (6.5 vs 19.2 mM) and an increased V max/K m value (8.0 × 10–3 vs 5.8 × 10–3 min–1), respectively. Furthermore, the as-prepared SEH@UiO-66-NH2, for the first time, was successfully applied as an efficient biocatalyst for the asymmetric hydrolysis of 1,2-epoxyoctane to (R)-1,2-octanediol in a novel deep eutectic solvent (DES) with a yield of around 41.4% and a product e.e. value of 81.2%. Remarkably, the nano-/microscale UiO-66-NH2 MOFs as novel enzyme support materials are promising for enzyme immobilization, and the prepared SEH@UiO-66-NH2 exhibited great potential for efficient biosynthesis of enantipure (R)-1,2-octanediol.

Toxoplasmosis remains a world-threatening disease largely because of the lack of a fully effective vaccine. Here, we created a ΔGRA17 mutant by disrupting the virulence factor GRA17 using CRISPR-Cas9 method. Then, we tested whether ΔGRA17 tachyzoites can be used as a live-attenuated vaccine against acute, chronic, and congenital Toxoplasma gondii infection in mice. Immune response evoked by ΔGRA17 immunization suggested a sequential Th1 and Th2 T cell response, indicated by high levels of Th1 and a mixed Th1/Th2 cytokines at 28 and 70 days after immunization, respectively. ΔGRA17-mediated immunity fully protected mice against lethal infection with wild-type (wt) RH strain, heterologous challenge with PYS, and TgC7 strains of the Chinese ToxoDB#9 genotype, and T. gondii Pru strain. Although parasite cysts were detected in 8 out of 10 immunized mice, cyst burden in the brain was significantly reduced (P < 0.05) in immunized mice (53 ± 15 cysts/brain) compared to non-immunized mice (4,296 ± 687 cysts/brain). In respect to congenital infection, the litter size, survival rate, and body weight (BW) of pups born to ΔGRA17-immunized dams were not different compared to pups born to naïve control dams (P = 0.24). However, a marked reduction in the litter size (P < 0.001), survival rate, and BW (P < 0.01) of pups born to non-immunized and infected dams was detected. Also, immunized dams infected with type II Pru strain had significantly (P < 0.001) less cyst burden in the brain compared with non-immunized and infected dams. These findings show that immunization with ΔGRA17 strain evokes cell-mediated and neutralizing antibody responses and confers some degree of protection against challenge with homologous and heterologous virulent T. gondii strains.

No abstract